A sleep-deprived rat runs a maze at full speed. A narcoleptic dog wakes up and stays awake. A researcher staring at a vial of lyophilized powder thinks: *how much of this do I actually give?*
That's the question this guide answers.
You already know what Orexin-A does — it binds OX1R and OX2R receptors in the hypothalamus, locus coeruleus, and prefrontal cortex, driving wakefulness, attention, and reward-circuit engagement. You know it's a 33-amino-acid neuropeptide with a molecular weight of approximately 3,562 Da, produced primarily in the lateral hypothalamic area. You know why it's interesting.
What you need now is the protocol math: how to reconstitute it, what dose to start with, how often to administer it, how long a cycle should run, and what to stack it with when you're ready to go deeper. That's what this guide delivers — in granular, actionable detail.
---
Why Dosing Orexin-A Is Genuinely Complicated
Most peptides follow a fairly predictable dose-response curve. Orexin-A doesn't behave that simply, and understanding why will make you a better researcher.
First, route of administration dramatically changes bioavailability. Orexin-A is a large, relatively hydrophilic peptide. Peripheral subcutaneous injection delivers it to systemic circulation, but the blood-brain barrier presents a significant obstacle. Intranasal administration bypasses this problem almost entirely — the trigeminal and olfactory nerve pathways provide direct access to the CNS, and several studies in non-human primates and rodents confirm that intranasal Orexin-A reaches the cerebrospinal fluid and cortex within 20–30 minutes.
Second, receptor saturation is rapid. OX1R and OX2R have high affinity for native Orexin-A (Ki values in the low nanomolar range). This means the difference between an effective dose and a supraphysiological one is narrower than with many other peptides. Flooding receptors doesn't produce linearly better effects — it produces receptor desensitization.
Third, the peptide is metabolically unstable. Orexin-A has a half-life in plasma of roughly 20–30 minutes following peripheral injection due to proteolytic cleavage. Intranasal delivery produces CNS effects that outlast this, suggesting the relevant half-life in neural tissue is longer, but researchers should plan dosing schedules around the short peripheral window.
Fourth, endogenous Orexin-A fluctuates dramatically across the circadian cycle — peaking in the active phase and dropping near-zero during sleep. Exogenous administration that ignores circadian context risks either wasted peptide (if given when endogenous levels are already high) or circadian disruption (if given at the wrong time).
Keep all four of these factors in mind throughout the protocol sections below.
---
Reconstitution: The Math You Need Before Anything Else
Orexin-A arrives as a lyophilized (freeze-dried) powder, typically in vials of 100 mcg, 500 mcg, or 1 mg. Before you can dose it, you need to reconstitute it correctly.
What to Use for Reconstitution
Bacteriostatic water (BW) is the standard reconstitution vehicle for Orexin-A in research settings. It contains 0.9% benzyl alcohol as a preservative, which extends the shelf life of your reconstituted solution to approximately 4–6 weeks refrigerated (2–8°C). Sterile water works but reduces shelf life to roughly 3–5 days.
Do not use saline for reconstitution if you're planning intranasal administration — the sodium chloride can irritate nasal mucosa at peptide concentrations. For intranasal use, sterile water or a dedicated intranasal peptide vehicle (e.g., a 0.9% NaCl solution with a small amount of cyclodextrin as a permeation enhancer) is preferred.
Orexin-A is generally soluble in water at research concentrations. Some researchers add 1–2% DMSO if solubility issues arise at higher concentrations, but this is rarely necessary below 1 mg/mL.
Reconstitution Calculation Table
The formula is simple: Concentration (mcg/mL) = Peptide Amount (mcg) ÷ Volume of BW Added (mL)
| Vial Size | BW Added | Resulting Concentration | Volume Per 10 mcg Dose | Volume Per 25 mcg Dose |
|---|---|---|---|---|
| 100 mcg | 1.0 mL | 100 mcg/mL | 0.10 mL (10 units on U-100 syringe) | 0.25 mL (25 units) |
| 100 mcg | 2.0 mL | 50 mcg/mL | 0.20 mL (20 units) | 0.50 mL (50 units) |
| 500 mcg | 2.5 mL | 200 mcg/mL | 0.05 mL (5 units) | 0.125 mL (12.5 units) |
| 500 mcg | 5.0 mL | 100 mcg/mL | 0.10 mL (10 units) | 0.25 mL (25 units) |
| 1 mg | 5.0 mL | 200 mcg/mL | 0.05 mL (5 units) | 0.125 mL (12.5 units) |
| 1 mg | 10.0 mL | 100 mcg/mL | 0.10 mL (10 units) | 0.25 mL (25 units) |
Practical recommendation: Reconstitute to 100 mcg/mL regardless of vial size. This concentration makes dose math straightforward — every 10 units on a U-100 insulin syringe delivers exactly 10 mcg. It's the concentration used in most preclinical studies, and it minimizes pipetting errors.
Step-by-Step Reconstitution Protocol
1. Remove both vials (peptide and BW) from refrigerator. Allow to reach room temperature over 15–20 minutes — this reduces thermal shock to the peptide.
2. Wipe rubber stoppers of both vials with an alcohol swab. Allow to dry completely (30 seconds).
3. Draw the calculated volume of bacteriostatic water into a 1 mL syringe.
4. Insert needle into the peptide vial at a 45-degree angle. Inject the BW slowly down the side of the vial — do not aim the stream directly at the lyophilized cake. This prevents peptide degradation from mechanical shear.
5. Do not shake. Gently roll the vial between your palms for 30–60 seconds until the powder is fully dissolved. The solution should be clear and colorless.
6. Label the vial with the date of reconstitution and the concentration.
7. Store at 2–8°C. Protect from light.
⚠️ Critical note: Orexin-A is sensitive to repeated freeze-thaw cycles. Once reconstituted, do not refreeze. If you anticipate using less than a full vial within 4–6 weeks, consider reconstituting only a portion and leaving the remainder as lyophilized powder (which is stable at −20°C for 12+ months).
---
Intranasal Administration: Equipment and Technique
Because intranasal delivery is the most pharmacologically relevant route for CNS Orexin-A research, it deserves its own technical section.
Equipment
Low-dead-volume intranasal atomizer device: (e.g., MAD Nasal™ or equivalent mucosal atomization device). These convert liquid into a fine mist that deposits on the nasal mucosa rather than dripping into the throat.
1 mL luer-lock syringe
The reconstituted peptide solution
Volume Constraints
The nasal mucosa can absorb approximately 100–150 µL per nostril before liquid begins draining into the throat, where it's swallowed and largely degraded. This means:
Maximum per-nostril volume:: 100–150 µL (0.10–0.15 mL)
Maximum per-administration volume (both nostrils):: 200–300 µL (0.20–0.30 mL)
This volume constraint directly dictates your reconstitution concentration. If your target dose is 100 mcg intranasally and you reconstitute to 100 mcg/mL, you'd need to administer 1.0 mL — far exceeding nasal capacity. For intranasal work, reconstitute to higher concentrations:
| Target Dose | Recommended Concentration for Intranasal Use | Volume Per Nostril |
|---|---|---|
| 25 mcg | 250 mcg/mL | 50 µL per nostril |
| 50 mcg | 500 mcg/mL | 50 µL per nostril |
| 100 mcg | 500 mcg/mL | 100 µL per nostril |
| 200 mcg | 1,000 mcg/mL | 100 µL per nostril |
Technique
1. Tilt the research subject's head slightly back.
2. Insert the atomizer tip just inside one nostril, angled slightly toward the outer wall (away from the septum).
3. Deliver half the calculated volume to each nostril in a single smooth depression of the plunger.
4. Have the subject sniff gently — this draws the mist toward the olfactory epithelium in the upper nasal cavity rather than letting it pool in the lower passages.
5. Administer approximately 2 minutes apart between nostrils to allow initial absorption before the second dose.
---
The Dosing Framework: How Preclinical Data Translates to Research Protocols
Human dosing data for Orexin-A is extremely limited. The most well-known human study — Deadwyler et al. (2007), published in *Journal of Neuroscience* — used intranasal Orexin-A in rhesus monkeys and humans with sleep deprivation, finding that ~200 mcg intranasally restored cognitive performance to rested baseline in sleep-deprived subjects. This is the anchor data point for human-scale research.
Preclinical rodent studies typically use doses in the 0.3–3 nmol range administered intracerebroventricularly (ICV) or 10–100 mcg/kg subcutaneously. Translating rodent doses to human equivalents using standard body surface area scaling (multiply rodent mg/kg by 0.081 for a 70 kg human) yields rough human equivalent doses of approximately 30–250 mcg per administration depending on the source study.
Below are three tiered protocols based on this data.
---
Protocol 1: Beginner Research Protocol
Target: Establishing baseline response, assessing tolerability, identifying individual sensitivity
Route: Intranasal (preferred) or subcutaneous
Starting Dose: 10–25 mcg per administration
This is a conservative entry point. It's well below the doses used in the Deadwyler human study but allows researchers to assess receptor sensitivity, note any side effects (particularly cardiovascular — Orexin-A does activate sympathetic tone), and establish a personal baseline before escalating.
Beginner Protocol Table
| Week | Dose | Frequency | Route | Timing | Notes |
|---|---|---|---|---|---|
| 1 | 10 mcg | Once daily | Intranasal or SubQ | Morning, within 30 min of waking | Assess baseline response for 48h |
| 2 | 15 mcg | Once daily | Intranasal | Morning | Note wakefulness quality, mood |
| 3 | 20 mcg | Once daily | Intranasal | Morning | Begin tracking cognitive metrics |
| 4 | 25 mcg | Once daily | Intranasal | Morning or pre-task | Consider titrating to Standard Protocol |
Cycle length: 4 weeks on, 2 weeks off minimum
What to track: Sleep onset latency, morning alertness (subjective 1–10), reaction time tests, heart rate at rest, any appetite changes (Orexin-A has orexigenic effects at higher doses), anxiety or agitation
Reconstitution for beginners: Use 100 mcg/mL concentration. This makes measuring 10–25 mcg doses straightforward on a standard U-100 insulin syringe (10–25 units).
---
Protocol 2: Standard Research Protocol
Target: Wakefulness enhancement, attention optimization, cognitive performance during sleep deprivation or shift-work simulation
Route: Intranasal (strongly preferred for CNS effects)
Dose Range: 50–100 mcg per administration
This range maps most closely to the Deadwyler et al. human/primate data and to the doses used in the Bhaskaran and Smith (2011) rat studies showing improved working memory performance. The 100 mcg dose is the most-studied single dose in human-adjacent research.
Standard Protocol Table
| Parameter | Specification |
|---|---|
| Dose | 75–100 mcg per administration |
| Route | Intranasal (split equally between nostrils) |
| Frequency | Once daily, or twice daily during acute sleep deprivation protocols |
| Timing | 30–60 minutes before cognitive testing or work period |
| Cycle length | 4–6 weeks active |
| Off period | 2–4 weeks minimum |
| Reconstitution | 500 mcg/mL (allows 100 mcg in 200 µL total volume — 100 µL per nostril) |
Twice-Daily Standard Protocol (Acute Sleep Deprivation Research)
For researchers studying acute sleep deprivation scenarios (e.g., 24–36 hour wakefulness protocols), twice-daily dosing is supported by the pharmacokinetic data:
| Time Point | Dose | Notes |
|---|---|---|
| 0h (baseline) | 100 mcg intranasal | Administered before sleep deprivation begins |
| 8h | 75 mcg intranasal | Mid-protocol maintenance dose |
| 16h | 75 mcg intranasal | If protocol extends beyond 16h |
| 24h | 50 mcg intranasal | Reduced dose; allow recovery sleep to follow |
Key finding from Deadwyler et al. (2007): A single 200 mcg intranasal dose in rhesus monkeys sleep-deprived for 30–36 hours restored performance on a delayed match-to-sample task to within 90% of well-rested baseline. Placebo-treated sleep-deprived animals showed ~50% performance decline. This is the clearest human-adjacent data point for acute cognitive rescue use.
Important timing note: Do not administer within 4–5 hours of intended sleep. Orexin-A's wake-promoting effects, particularly via the locus coeruleus noradrenergic system, can significantly increase sleep onset latency if given too close to bedtime. This is not just ineffective — it can worsen the sleep deprivation you're trying to study.
---
Protocol 3: Advanced Research Protocol
Target: Maximal wakefulness, attention, and reward-circuit engagement; combination protocols; extended research cycles
Route: Intranasal with optional subcutaneous supplementation
Dose Range: 150–300 mcg per administration (intranasal)
The upper end of this range aligns with the Deadwyler study's most effective dose. Beyond 300 mcg, there is no preclinical evidence of additional cognitive benefit, and the risk of receptor desensitization and cardiovascular side effects (tachycardia, elevated blood pressure) increases substantially.
Advanced Protocol Structure
| Phase | Duration | Dose | Frequency | Notes |
|---|---|---|---|---|
| Loading | Week 1–2 | 100 mcg/day | Once daily (AM) | Establish receptor sensitivity baseline |
| Active | Week 3–8 | 150–200 mcg/day | Once daily (AM) or split AM/midday | Core research window |
| Peak | Week 9–10 | 200–300 mcg/day | Once daily, pre-task | Only if well-tolerated |
| Off | Week 11–14 | None | — | Full receptor recovery period |
Subcutaneous Supplementation Option
Some researchers combine intranasal Orexin-A (for CNS effects) with a low-dose subcutaneous injection (for peripheral and systemic orexinergic signaling). This mirrors the natural physiological state where Orexin-A acts both centrally and peripherally.
| Component | Dose | Route | Timing |
|---|---|---|---|
| CNS dose | 100–150 mcg | Intranasal | Morning |
| Peripheral dose | 25–50 mcg | SubQ | 30 min after intranasal |
Rationale: Peripheral Orexin-A signaling contributes to metabolic regulation, appetite, and autonomic tone. Intranasal dosing alone misses these pathways. Combined administration is more physiologically complete but also increases systemic exposure and side effect risk.
---
Cycle Length and Off-Period Rationale
One of the most common errors in Orexin-A research protocols is running cycles too long without adequate off periods. Here's why this matters mechanically:
OX1R and OX2R undergo agonist-induced internalization — when continuously activated, the receptors are trafficked away from the cell surface into endosomes, reducing sensitivity. In rodent models, continuous ICV Orexin-A infusion for 7+ days produces measurable receptor downregulation and reduced wake-promoting efficacy.
The practical implication: cycles longer than 8–10 weeks without a break are likely to show diminishing returns, and possibly rebound hypersomnia during the off period as the now-sensitized system overcompensates.
Recommended Cycle Structures
| Cycle Type | Active Period | Off Period | Best For |
|---|---|---|---|
| Short pulse | 1–2 weeks | 1 week | Acute event (exam, shift work study) |
| Standard | 4–6 weeks | 2–4 weeks | Chronic wakefulness research |
| Extended | 8–10 weeks | 4–6 weeks | Long-term cognitive protocol |
| Pulsed | 5 days on, 2 days off | Continuous | Minimizes receptor adaptation |
The 5-days-on, 2-days-off pulsed approach is worth highlighting. It mirrors natural workweek patterns and provides weekend receptor recovery without a full off-cycle. Several researchers in the nootropic peptide space report better sustained efficacy with this approach compared to continuous daily dosing.
---
Stacking Orexin-A: Synergistic Protocols
Orexin-A doesn't act in isolation in the brain — it's deeply embedded in a network of wakefulness, attention, and reward circuits. Strategic stacking can enhance its effects or address aspects of cognition that Orexin-A alone doesn't cover.
Stack 1: Orexin-A + Semax — The Focus Stack
Rationale: Orexin-A drives wakefulness and arousal via the noradrenergic and histaminergic systems. Semax enhances BDNF production and dopaminergic/serotonergic tone in the prefrontal cortex, improving higher-order executive function, working memory, and stress resilience. These two peptides work on complementary circuits — Orexin-A turns the arousal dial up, Semax sharpens what that arousal is applied to.
| Component | Dose | Route | Timing |
|---|---|---|---|
| Orexin-A | 75–100 mcg | Intranasal | Morning, upon waking |
| Semax | 300–600 mcg | Intranasal | 30 minutes after Orexin-A |
Cycle: 4 weeks on, 2 weeks off
Expected synergy: Improved sustained attention, faster task-switching, reduced cognitive fatigue during extended work sessions
Watch for: Overstimulation, anxiety, elevated resting heart rate. Start at the lower end of both doses.
Stack 2: Orexin-A + Selank — The Calm Alertness Stack
Rationale: Orexin-A's wake-promoting effects can tip into anxious hyperarousal in sensitive researchers, particularly at doses above 100 mcg. Selank — a synthetic analog of Tuftsin — modulates the GABA-A system and reduces anxiety without sedation. This combination aims to produce the alert-but-calm state associated with peak cognitive performance, similar to the "flow state" described in performance psychology.
| Component | Dose | Route | Timing |
|---|---|---|---|
| Orexin-A | 50–75 mcg | Intranasal | Morning |
| Selank | 250–500 mcg | Intranasal | Simultaneously or up to 15 min after |
Cycle: 4–6 weeks on, 2 weeks off
Expected synergy: Wakefulness without jitteriness, improved mood regulation, reduced cortisol response to cognitive stress tasks
Watch for: Selank's anxiolytic effects are generally mild, but combining with Orexin-A's sympathetic activation means blood pressure monitoring is prudent.
Stack 3: Orexin-A + DSIP — The Circadian Optimization Stack
Rationale: This isn't a simultaneous stack — it's a temporal one. Delta Sleep-Inducing Peptide (DSIP) is administered in the evening to improve sleep quality and architecture, while Orexin-A is administered in the morning to sharpen the wake phase. The goal is to maximize both poles of the sleep-wake cycle, improving the overall quality of the circadian rhythm rather than just suppressing one phase.
| Component | Dose | Route | Timing |
|---|---|---|---|
| Orexin-A | 75–100 mcg | Intranasal | Within 30 min of waking |
| DSIP | 100–200 mcg | SubQ | 30–60 min before intended sleep |
Cycle: 6 weeks on, 2 weeks off
Expected synergy: Sharper morning alertness, deeper slow-wave sleep, improved memory consolidation (which occurs predominantly during deep sleep), reduced daytime fatigue
Watch for: DSIP has its own receptor kinetics and tolerability profile — research both independently before combining.
---
Timing Optimization: When to Dose for Maximum Effect
Timing matters as much as dose for Orexin-A. Here's the evidence-based framework:
Optimal window for wakefulness research: Administer 20–30 minutes before the target cognitive task or work period. Intranasal onset is approximately 15–25 minutes; subcutaneous onset is 30–45 minutes.
Circadian alignment: Endogenous Orexin-A peaks during the active phase — roughly 8 AM to 2 PM in diurnal subjects. Exogenous administration during this window works with the system. Administration in the early morning (6–8 AM) is particularly potent because it coincides with the natural cortisol awakening response, and these two systems appear to be synergistic.
Pre-cognitive-task dosing: For acute cognitive enhancement (exam, presentation, shift-work simulation), dosing 30 minutes before the task is optimal. The Deadwyler study used this exact timing in their primate protocol.
What to avoid:
Dosing within 4–5 hours of intended sleep (disrupts sleep onset)
Dosing on an empty stomach at high doses (may exacerbate orexigenic effects and hunger-driven distraction)
Dosing more than twice daily in any 24-hour period (receptor saturation, no additional benefit)
---
Dose-Response Relationship: What the Data Actually Shows
Understanding the dose-response curve prevents the common mistake of assuming more is always better.
| Dose Range | Expected Effects | Supporting Data |
|---|---|---|
| 1–10 mcg (SubQ) | Minimal to no CNS effect; some peripheral sympathetic activation | Rodent pharmacokinetic studies |
| 10–50 mcg (Intranasal) | Mild wakefulness promotion, slight attention improvement | Extrapolated from primate data |
| 75–150 mcg (Intranasal) | Clear wakefulness, attention restoration, working memory improvement in sleep-deprived models | Deadwyler et al. 2007 (200 mcg monkey data); Turner et al. 2010 |
| 200–300 mcg (Intranasal) | Maximum studied human-scale dose; full cognitive restoration in acute sleep deprivation | Deadwyler et al. 2007 (human pilot) |
| >300 mcg (Intranasal) | No additional cognitive benefit demonstrated; increased cardiovascular side effects | Extrapolated from OX receptor saturation pharmacology |
The dose-response curve for Orexin-A is relatively flat above 200 mcg intranasal. In the Deadwyler study, 200 mcg and 400 mcg produced statistically equivalent cognitive performance improvements. Going above 200 mcg doesn't buy more cognition — it buys more side effects.
---
Safety Profile: What Researchers Need to Know
Common Side Effects
Cardiovascular activation is the most consistent side effect at doses above 100 mcg. Orexin-A directly activates the locus coeruleus, which projects noradrenergic fibers throughout the brain and autonomic nervous system. Expect:
Heart rate increase of 5–15 BPM at 100–200 mcg doses (documented in human subjects)
Mild systolic blood pressure elevation (typically 5–10 mmHg)
These effects are transient, peaking at 30–60 minutes post-administration and resolving within 2–3 hours
Appetite stimulation. Orexin-A is orexigenic — its name derives from the Greek *orexis* (appetite). At doses above 100 mcg, researchers should expect increased hunger, particularly for calorie-dense foods. This is mediated through hypothalamic NPY/AgRP neurons and is dose-dependent. Plan research protocols around meal timing accordingly.
Mild anxiety or agitation at higher doses (>150 mcg), particularly in researchers who are already sensitive to stimulant-like compounds. This appears to be mediated through OX1R activation in the amygdala and is more pronounced in subjects with baseline anxiety.
Nasal irritation with intranasal administration, particularly at high concentrations (>500 mcg/mL). Use a properly formulated vehicle and a mucosal atomizer to minimize this.
Rare and Theoretical Risks
Receptor desensitization. Extended continuous use (>8–10 weeks) risks OX1R/OX2R downregulation. The clinical consequence would be rebound hypersomnolence during off-periods. Mitigated by structured cycling.
Sleep architecture disruption. Orexin-A suppresses REM sleep when present at high concentrations during the sleep phase. If administration occurs too close to bedtime, expect delayed sleep onset and reduced REM in the first sleep cycle. This is why the 4–5 hour pre-sleep buffer is non-negotiable.
Interaction with existing medications. Orexin-A's sympathomimetic effects may be additive with stimulant medications (amphetamines, modafinil, methylphenidate). Researchers using these compounds should not stack with Orexin-A without careful cardiovascular monitoring.
Contraindications
Hypertension: (resting BP >140/90): Orexin-A's sympathetic activation may push BP into dangerous ranges
Cardiac arrhythmias: Increased sympathetic tone may exacerbate existing arrhythmias
Severe anxiety disorders: OX1R activation in the amygdala can worsen anxiety in predisposed individuals
Narcolepsy/cataplexy with active OX2R deficiency: While Orexin-A is theoretically therapeutic here, the pharmacokinetics of exogenous administration are not well-characterized enough for safe human use outside clinical settings
---
Compared to Alternative Wakefulness-Promoting Compounds
| Feature | Orexin-A (Intranasal) | Modafinil | Semax | Selank |
|---|---|---|---|---|
| Mechanism | OX1R/OX2R agonism, noradrenergic/histaminergic | Dopamine reuptake inhibition, histamine | BDNF upregulation, dopaminergic | GABA-A modulation, anxiolytic |
| Onset | 15–25 min | 45–90 min | 20–30 min | 15–20 min |
| Duration | 3–5 hours | 8–12 hours | 4–6 hours | 4–8 hours |
| Sleep disruption risk | High if mistimed | High | Low | Very low |
| Cognitive domain | Wakefulness, attention, working memory | Executive function, wakefulness | Memory, executive function, mood | Anxiety, baseline cognition |
| Appetite effect | Increases appetite | Decreases appetite | Neutral | Neutral |
| Cardiovascular risk | Moderate (sympathetic activation) | Low-moderate | Low | Very low |
| Tolerance risk | Moderate (receptor desensitization) | Low-moderate | Low | Low |
| Research grade cost | High | Low (generic) | Moderate | Moderate |
| Human data | Very limited | Extensive | Limited | Limited |
Orexin-A occupies a unique niche: it's the only compound here that directly targets the endogenous wakefulness signaling system at the receptor level. Every other option works downstream of this system or through parallel circuits. This makes it both more targeted and more complex to use correctly.
---
Storage: Keeping Your Orexin-A Potent
Orexin-A is a medium-stability peptide. It's not as fragile as some growth factors, but it's not as robust as BPC-157 either. Follow these guidelines:
Lyophilized powder (unreconstituted):
Room temperature: Stable for 1–3 months if away from humidity and light
Refrigerated (2–8°C): Stable for 12–18 months
Frozen (−20°C): Stable for 24+ months
Deep frozen (−80°C): Stable indefinitely for research purposes
Reconstituted solution:
Room temperature: Use within 24 hours
Refrigerated (2–8°C) with bacteriostatic water: 4–6 weeks
Refrigerated (2–8°C) with sterile water: 3–5 days
Do not freeze reconstituted solution: — ice crystal formation damages the peptide structure
Light sensitivity: Orexin-A is mildly photosensitive. Store in amber vials or wrap clear vials in foil after reconstitution.
Signs of degradation: A reconstituted solution that turns yellow, cloudy, or develops visible particulates should be discarded. Clear and colorless is the standard.
---
Practical Titration Guide: How to Find Your Optimal Dose
Titration is the process of finding the minimum effective dose for a given research subject — the dose that produces the desired effect with minimal side effects. For Orexin-A, this matters because individual sensitivity varies significantly based on baseline orexinergic tone, OX receptor density, and circadian phenotype.
The Titration Protocol
Week 1: 10 mcg intranasal every morning. Record: subjective alertness at 30 min, 1h, 2h post-dose; heart rate; any side effects.
Week 2: If no meaningful effect and no significant side effects, increase to 25 mcg. Continue daily logging.
Week 3: If still subthreshold, increase to 50 mcg. At this dose, most subjects should notice measurable wakefulness enhancement.
Week 4: If target effect achieved at 50 mcg, maintain. If not, increase to 75 mcg.
Week 5+: Continue titrating by 25 mcg increments until target effect achieved or side effects become limiting. For most researchers, the effective dose falls between 50–150 mcg intranasal.
Stop titrating and maintain current dose if:
Heart rate increases >20 BPM above baseline
Resting systolic BP rises >15 mmHg above baseline
Anxiety or agitation becomes distracting
The desired cognitive effect is clearly achieved
---
What's Coming Next in Orexin-A Research
The field is moving fast, and the dosing landscape may shift substantially over the next 3–5 years.
Pharmaceutical OX2R agonists (like suvorexant's mechanistic inverse — compounds that activate rather than block OX2R) are in early development at several labs. These synthetic agonists aim to replicate Orexin-A's wake-promoting effects with improved BBB penetration and oral bioavailability. If successful, they would render intranasal peptide administration largely obsolete for wakefulness applications.
Lipidated Orexin-A analogs are being studied to extend the half-life from 20–30 minutes to 4–8 hours while maintaining BBB penetration. This would allow once-daily dosing with sustained CNS effects — a significant improvement over current protocols.
Intranasal delivery optimization is an active research area. Cyclodextrin complexation and chitosan-based nanoparticle delivery systems have both shown in animal models that they can increase nasal-to-CNS transport of Orexin-A by 2–4x compared to simple aqueous solution. This means future optimized formulations may achieve the same CNS effect at significantly lower doses.
The narcolepsy angle remains the most clinically pressing question. Whether exogenous Orexin-A can serve as a practical replacement therapy for orexin-deficient narcolepsy patients — replacing the lost hypothalamic neurons' output — depends on resolving the delivery and half-life challenges. Phase 2 trials of intranasal Orexin-A in narcolepsy patients have shown preliminary efficacy but are limited by the short duration of action.
Memory consolidation protocols are an emerging application. Several rodent studies (including Jaeger et al., 2002, and Wayner et al., 2004) show that Orexin-A administered around the time of learning — not just for wakefulness — enhances memory consolidation. The specific timing question (pre-learning vs. post-learning) and the dose required for this effect independent of wakefulness are not yet resolved.
---
Key Takeaways
Route determines pharmacology.: Intranasal Orexin-A reaches the CNS directly via olfactory/trigeminal pathways and is the preferred route for cognitive research. Subcutaneous is appropriate for peripheral/systemic research.
The anchor dose is 100–200 mcg intranasal.: This is the range with the strongest human-adjacent evidence (Deadwyler et al., 2007). Start lower (10–25 mcg) and titrate up.
Reconstitute to 500 mcg/mL for intranasal use: to stay within nasal volume constraints (≤100 µL per nostril).
Timing is critical.: Administer 20–30 minutes before the target cognitive task. Never within 4–5 hours of intended sleep.
The dose-response curve flattens above 200 mcg.: Going higher buys cardiovascular side effects, not better cognition.
Cycle lengths should not exceed 8–10 weeks: without a 2–4 week off period to prevent OX1R/OX2R desensitization and rebound hypersomnia.
The 5-days-on, 2-days-off pulsed protocol: offers a practical middle ground between continuous dosing and full off-cycles, helping maintain receptor sensitivity.
Stacking with Semax enhances executive function;: stacking with Selank reduces anxiety-driven overstimulation; pairing with DSIP in the evening optimizes the full sleep-wake cycle.
Cardiovascular monitoring is non-negotiable: at doses above 100 mcg — expect heart rate and blood pressure increases that are real and dose-dependent.
Lyophilized Orexin-A is stable for 24+ months at −20°C.: Reconstituted solution should be used within 4–6 weeks (with bacteriostatic water) and never refrozen.
---
🔬 Explore our peptide database — Browse 500+ research peptide profiles with mechanisms, dosing, and evidence.
🛒 Ready to buy? — Browse our verified vendor shop for third-party tested peptides.
🤖 Have questions about your specific protocol? — Ask PeptideAI for personalized guidance on Orexin-A dosing and stacking.
📚 Want more guides? — Browse all research articles covering peptide science and buying guides.
---